BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nelson JE, Bhattacharya R, Lindor KD, Chalasani N, Raaka S, Heathcote EJ, Miskovsky E, Shaffer E, Rulyak SJ, Kowdley KV. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology. 2007;46:723-729. [PMID: 17680648 DOI: 10.1002/hep.21742] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Koek G, Liedorp P, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clinica Chimica Acta 2011;412:1297-305. [DOI: 10.1016/j.cca.2011.04.013] [Cited by in Crossref: 202] [Cited by in F6Publishing: 195] [Article Influence: 18.4] [Reference Citation Analysis]
2 Ahmed U, Latham PS, Oates PS. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol 2012; 18(34): 4651-4658 [PMID: 23002334 DOI: 10.3748/wjg.v18.i34.4651] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
3 Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol. 2009;25:223-229. [PMID: 19396960 DOI: 10.1097/MOG.0b013e3283279668] [Cited by in Crossref: 149] [Cited by in F6Publishing: 82] [Article Influence: 11.5] [Reference Citation Analysis]
4 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17. [PMID: 27657051 DOI: 10.3390/ijms17091575] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 13.2] [Reference Citation Analysis]
6 Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl). 2012;90:105-118. [PMID: 21894552 DOI: 10.1007/s00109-011-0803-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
7 Kovac U, Rozman D. Genetics of Non-alcoholic Fatty Liver Disease. In: John Wiley & Sons Ltd, editor. eLS. Chichester: John Wiley & Sons, Ltd; 2001. pp. 1-8. [DOI: 10.1002/9780470015902.a0025335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
8 Yoshioka S, Hamada A, Jobu K, Yokota J, Onogawa M, Kyotani S, Miyamura M, Saibara T, Onishi S, Nishioka Y. Effects of Eriobotrya japonica seed extract on oxidative stress in rats with non-alcoholic steatohepatitis. Journal of Pharmacy and Pharmacology 2010;62:241-6. [DOI: 10.1211/jpp.62.02.0012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
9 Tan TC, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, Bridle KR, Anderson GJ, Fletcher LM. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest. 2013;93:1295-1312. [PMID: 24126888 DOI: 10.1038/labinvest.2013.121] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.8] [Reference Citation Analysis]
10 Lückhoff HK, Kruger FC, Kotze MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol 2015; 7(9): 1192-1208 [PMID: 26019735 DOI: 10.4254/wjh.v7.i9.1192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
11 Paisant A, Boulic A, Bardou-Jacquet E, Bannier E, d'Assignies G, Lainé F, Turlin B, Gandon Y. Assessment of liver iron overload by 3 T MRI. Abdom Radiol (NY) 2017;42:1713-20. [PMID: 28224171 DOI: 10.1007/s00261-017-1077-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
12 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
13 de Alwis NMW, Day CP. Genes and nonalcoholic fatty liver disease. Curr Diab Rep 2008;8:156-63. [DOI: 10.1007/s11892-008-0027-9] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
14 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 28.8] [Reference Citation Analysis]
15 Jung JY, Shim JJ, Park SK, Ryoo JH, Choi JM, Oh IH, Jung KW, Cho H, Ki M, Won YJ, Oh CM. Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population. Hepatol Int 2019;13:222-33. [PMID: 30182166 DOI: 10.1007/s12072-018-9892-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
17 Li H, Wang L, Yan X, Liu Q, Yu C, Wei H, Li Y, Zhang X, He F, Jiang Y. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J Proteome Res 2011;10:2797-806. [PMID: 21563774 DOI: 10.1021/pr200047c] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
18 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011;52:593-617. [PMID: 21245030 DOI: 10.1194/jlr.R008896] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
19 Juzėnas S, Kupčinskas J, Valantienė I, Šumskienė J, Petrenkienė V, Kondrackienė J, Kučinskas L, Kiudelis G, Skiecevičienė J, Kupčinskas L. Association of HFE gene C282Y and H63D mutations with liver cirrhosis in the Lithuanian population. Medicina (Kaunas) 2016;52:269-75. [PMID: 27816425 DOI: 10.1016/j.medici.2016.09.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Valenti L, Dongiovanni P, Fracanzani AL, Fargion S. HFE mutations in nonalcoholic fatty liver disease. Hepatology. 2008;47:1794-1795; author reply 1795-1796. [PMID: 18438784 DOI: 10.1002/hep.22059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
21 Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology. 2012;56:1730-1740. [PMID: 22611049 DOI: 10.1002/hep.25856] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
22 Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010;138:905-912. [PMID: 19931264 DOI: 10.1053/j.gastro.2009.11.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 170] [Article Influence: 14.0] [Reference Citation Analysis]
23 Radicheva MP, Andonova AN, Milcheva HT, Ivanova NG, Kyuchukova SG, Nikolova MS, Platikanova AS. Serum Markers of Iron Metabolism in Chronic Liver Diseases. Open Access Maced J Med Sci 2018;6:1010-6. [PMID: 29983793 DOI: 10.3889/oamjms.2018.251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Loréal O, Cavey T, Robin F, Kenawi M, Guggenbuhl P, Brissot P. Iron as a Therapeutic Target in HFE-Related Hemochromatosis: Usual and Novel Aspects. Pharmaceuticals (Basel) 2018;11:E131. [PMID: 30486249 DOI: 10.3390/ph11040131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Kwon JH, Park ST, Kim GD, You CR, Kim JD, Woo HY, Jang JW, Kim CW, Bae SH, Choi JY, Yoon SK. The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease. Korean J Hepatol 2009;15:59. [DOI: 10.3350/kjhep.2009.15.1.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
26 Tan TCH, Crawford DHG, Jaskowski LA, Murphy TM, Heritage ML, Subramaniam VN, Clouston AD, Anderson GJ, Fletcher LM. Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2011;301:G865-76. [DOI: 10.1152/ajpgi.00150.2011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
27 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448-457. [PMID: 21274866 DOI: 10.1002/hep.24038] [Cited by in Crossref: 171] [Cited by in F6Publishing: 159] [Article Influence: 14.3] [Reference Citation Analysis]
29 Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132. [PMID: 22126026 DOI: 10.1016/b978-0-12-387042-1.00006-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
30 Messner DJ, Rhieu BH, Kowdley KV. Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes. Dig Dis Sci. 2013;58:1899-1908. [PMID: 23558563 DOI: 10.1007/s10620-013-2648-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
31 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
32 Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. Journal of Hepatology 2011;55:920-32. [DOI: 10.1016/j.jhep.2011.05.008] [Cited by in Crossref: 183] [Cited by in F6Publishing: 172] [Article Influence: 16.6] [Reference Citation Analysis]
33 Terán Lantarón A, Crespo García J. [Non-alcoholic fatty liver disease. How and who to screen]. Gastroenterol Hepatol 2011;34:278-88. [PMID: 21429628 DOI: 10.1016/j.gastrohep.2010.11.010] [Reference Citation Analysis]
34 Hernaez R, Yeung E, Clark JM, Kowdley KV, Brancati FL, Kao WH. Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2011;55:1079-1085. [PMID: 21354231 DOI: 10.1016/j.jhep.2011.02.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
35 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 95.7] [Reference Citation Analysis]
36 Padda RS, Gkouvatsos K, Guido M, Mui J, Vali H, Pantopoulos K. A high-fat diet modulates iron metabolism but does not promote liver fibrosis in hemochromatotic Hjv⁻/⁻ mice. Am J Physiol Gastrointest Liver Physiol 2015;308:G251-61. [PMID: 25501544 DOI: 10.1152/ajpgi.00137.2014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
37 Shen HH, Alex R, Bellner L, Raffaele M, Licari M, Vanella L, Stec DE, Abraham NG. Milk thistle seed cold press oil attenuates markers of the metabolic syndrome in a mouse model of dietary-induced obesity. J Food Biochem 2020;44:e13522. [PMID: 33047319 DOI: 10.1111/jfbc.13522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1728-1744.e7. [PMID: 26873399 DOI: 10.1053/j.gastro.2016.01.037] [Cited by in Crossref: 121] [Cited by in F6Publishing: 116] [Article Influence: 20.2] [Reference Citation Analysis]
39 Fierro-Fine A, Guerin L, Hicsasmaz H, Brown KE. Clinical Factors Associated with Hepatocellular Iron Deposition in End-stage Liver Disease. J Clin Transl Hepatol 2020;8:231-9. [PMID: 33083244 DOI: 10.14218/JCTH.2020.00022] [Reference Citation Analysis]
40 Siddique A, Kowdley KV. Review article: the iron overload syndromes. Aliment Pharmacol Ther. 2012;35:876-893. [PMID: 22385471 DOI: 10.1111/j.1365-2036.2012.05051.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 7.8] [Reference Citation Analysis]
41 Raszeja-Wyszomirska J, Kurzawski G, Lawniczak M, Miezynska-Kurtycz J, Lubinski J. Nonalcoholic fatty liver disease and HFE gene mutations: A Polish study. World J Gastroenterol 2010; 16(20): 2531-2536 [PMID: 20503453 DOI: 10.3748/wjg.v16.i20.2531] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
42 Moya D, Baker SS, Liu W, Garrick M, Kozielski R, Baker RD, Zhu L. Novel pathway for iron deficiency in pediatric non-alcoholic steatohepatitis. Clin Nutr 2015;34:549-56. [PMID: 25000850 DOI: 10.1016/j.clnu.2014.06.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
43 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
44 Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, Mayo H, Singal AG. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198-210.e2. [PMID: 28970148 DOI: 10.1016/j.cgh.2017.09.041] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 20.6] [Reference Citation Analysis]
45 Manne V, Handa P, Kowdley KV. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:23-37. [PMID: 29128059 DOI: 10.1016/j.cld.2017.08.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 16.2] [Reference Citation Analysis]
46 Xu CF, Reck BH, Goodman VL, Xue Z, Huang L, Barnes MR, Koshy B, Spraggs CF, Mooser VE, Cardon LR, Pandite LN. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011;54:1237-43. [PMID: 21145803 DOI: 10.1016/j.jhep.2010.09.028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
47 Sacerdoti D, Singh SP, Schragenheim J, Bellner L, Vanella L, Raffaele M, Meissner A, Grant I, Favero G, Rezzani R, Rodella LF, Bamshad D, Lebovics E, Abraham NG. Development of NASH in Obese Mice is Confounded by Adipose Tissue Increase in Inflammatory NOV and Oxidative Stress. Int J Hepatol. 2018;2018:3484107. [PMID: 30057822 DOI: 10.1155/2018/3484107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
48 Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 2012;56:448-54. [PMID: 21756849 DOI: 10.1016/j.jhep.2011.05.029] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 9.7] [Reference Citation Analysis]
49 Valenti L, Moscatiello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM. 2011;104:141-149. [PMID: 20851820 DOI: 10.1093/qjmed/hcq170] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
50 Powell LW. A career forged in iron. Hepatology 2015;61:4-14. [PMID: 25043645 DOI: 10.1002/hep.27293] [Reference Citation Analysis]
51 Valenti L, Canavesi E, Galmozzi E, Dongiovanni P, Rametta R, Maggioni P, Maggioni M, Fracanzani AL, Fargion S. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2010;53:927-933. [PMID: 20739079 DOI: 10.1016/j.jhep.2010.05.023] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
52 Fracanzani AL, Valenti L, Bugianesi E, Vanni E, Grieco A, Miele L, Consonni D, Fatta E, Lombardi R, Marchesini G. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54:1244-1249. [PMID: 21145841 DOI: 10.1016/j.jhep.2010.09.037] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
53 Bloomer SA, Olivier AK, Bergmann OM, Mathahs MM, Broadhurst KA, Hicsasmaz H, Brown KE. Strain- and time-dependent alterations in hepatic iron metabolism in a murine model of nonalcoholic steatohepatitis. Cell Biochem Funct 2016;34:628-39. [PMID: 27935134 DOI: 10.1002/cbf.3238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
54 Vajro P, Lenta S, Socha P, Dhawan A, Mckiernan P, Baumann U, Durmaz O, Lacaille F, Mclin V, Nobili V. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee. Journal of Pediatric Gastroenterology & Nutrition 2012;54:700-13. [DOI: 10.1097/mpg.0b013e318252a13f] [Cited by in Crossref: 273] [Cited by in F6Publishing: 119] [Article Influence: 27.3] [Reference Citation Analysis]
55 Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep. 2012;14:8-16. [PMID: 22124850 DOI: 10.1007/s11894-011-0234-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 6.9] [Reference Citation Analysis]
56 Farrell GC. The liver and the waistline: Fifty years of growth. J Gastroenterol Hepatol. 2009;24 Suppl 3:S105-S118. [PMID: 19799688 DOI: 10.1111/j.1440-1746.2009.06080.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
57 Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. Gastroenterology. 2010;138:817-819. [PMID: 20116466 DOI: 10.1053/j.gastro.2010.01.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
58 Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015; 21(39): 11088-11111 [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
59 Atarashi M, Izawa T, Miyagi R, Ohji S, Hashimoto A, Kuwamura M, Yamate J. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Nutrients 2018;10:E175. [PMID: 29401710 DOI: 10.3390/nu10020175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
60 Wegermann K, Garrett ME, Zheng J, Coviello A, Moylan CA, Abdelmalek MF, Chow SC, Guy CD, Diehl AM, Ashley-Koch A, Suzuki A. Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. Hepatol Commun 2021;5:598-607. [PMID: 33860118 DOI: 10.1002/hep4.1668] [Reference Citation Analysis]
61 Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim Biophys Acta. 2011;1812:1557-1566. [PMID: 21840395 DOI: 10.1016/j.bbadis.2011.07.017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
62 Handa P, Maliken BD, Nelson JE, Hennessey KA, Akhila Vemulakonda L, Morgan-stevenson V, Dhillon BK, Gupta R, Yeh MM, Kowdley KV. Differences In Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis. Annals of Hepatology 2017;16:77-85. [DOI: 10.5604/16652681.1226818] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
63 Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2011;5:253-263. [PMID: 21476920 DOI: 10.1586/egh.11.18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
64 Yamamoto K, Yano I. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. Med Oncol 2018;35:16. [PMID: 29302760 DOI: 10.1007/s12032-017-1077-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res. 2009;39:213-222. [PMID: 19261002 DOI: 10.1111/j.1872-034x.2008.00442.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
66 Corradini E, Buzzetti E, Dongiovanni P, Scarlini S, Caleffi A, Pelusi S, Bernardis I, Ventura P, Rametta R, Tenedini E, Tagliafico E, Fracanzani AL, Fargion S, Pietrangelo A, Valenti LV. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology 2021;75:506-13. [DOI: 10.1016/j.jhep.2021.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kutlu O, Kaleli HN, Ozer E. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:8543763. [PMID: 30228976 DOI: 10.1155/2018/8543763] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
69 Choudhary NS, Duseja A. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol 2021;6:2. [PMID: 33409397 DOI: 10.21037/tgh.2019.09.06] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
70 Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol 2016; 22(29): 6742-6756 [PMID: 27547017 DOI: 10.3748/wjg.v22.i29.6742] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
71 Guo J, Hong F, Loke J, Yea S, Lim CL, Lee U, Mann DA, Walsh MJ, Sninsky JJ, Friedman SL. A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem 2010;285:5428-37. [PMID: 20022962 DOI: 10.1074/jbc.M109.035295] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
72 Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219-5238. [PMID: 23394097 DOI: 10.2174/13816128113199990381] [Cited by in Crossref: 128] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
73 Lee SH, Jeong SH, Lee D, Lee JH, Hwang SH, Cho YA, Park YS, Hwang JH, Kim JW, Kim N. An epidemiologic study on the incidence and significance of HFE mutations in a Korean cohort with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2010;44:e154-e161. [PMID: 20216079 DOI: 10.1097/mcg.0b013e3181d347d9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
74 Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta. 2009;1790:663-670. [PMID: 18848602 DOI: 10.1016/j.bbagen.2008.09.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
75 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 22.3] [Reference Citation Analysis]